VEGF/DLL4 binding agents and uses thereof
The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
1. A modified immunoglobulin molecule, comprising:
a) a first antigen-binding site that specifically binds human VEGF, and
b) a second antigen-binding site that specifically binds human DLL4; and
wherein the first antigen-binding site comprises a heavy chain CDR1 comprising NYWMH (SEQ ID NO:17), a heavy chain CDR2 comprising DINPSNGRTSYKEKFKR (SEQ ID NO:18), and a heavy chain CDR3 comprising HYDDKYYPLMDY (SEQ ID NO:19);
wherein the second antigen-binding site comprises a heavy chain CDR1 comprising TAYYIH (SEQ ID NO:13) or AYYIH (SEQ ID NO:79), a heavy chain CDR2 comprising YIANYNRATNYNQKFKG (SEQ ID NO:14), YISSYNGATNYNQKFKG (SEQ ID NO:15), YIAGYKDATNYNQKFKG (SEQ ID NO:59), or YISNYNRATNYNQKFKG (SEQ ID NO:65), and a heavy chain CDR3 comprising RDYDYDVGMDY (SEQ ID NO:16); and
wherein both the first and second-antigen binding sites comprise a light chain having at least 95% sequence identity to SEQ ID NO:4 that lacks signal sequence MVLQTQVFISLLLWISGAYG (amino acid residues 1-20 of SEQ ID NO:4).
2. The modified immunoglobulin molecule of claim 1 , wherein both the first and second antigen-binding sites comprise a light chain having at least 97% sequence identity to SEQ ID NO:4 that lacks signal sequence MVLQTQVFISLLLWISGAYG (amino acid residues 1-20 of SEQ ID NO:4).
3. The modified immunoglobulin molecule of claim 2 , wherein both the first and second antigen-binding sites comprise a light chain having at least 99% sequence identity to SEQ ID NO:4 that lacks signal sequence MVLQTQVFISLLLWISGAYG (amino acid residues 1-20 of SEQ ID NO:4).
4. The modified immunoglobulin molecule of claim 3 , wherein both the first and second antigen-binding sites comprise a light chain comprising SEQ ID NO:4 that lacks signal sequence MVLQTQVFISLLLWISGAYG (amino acid residues 1-20 of SEQ ID NO:4).
5. The modified immunoglobulin molecule of claim 4 , comprising a heavy chain of SEQ ID NO:7, a heavy chain of SEQ ID NO:62, and two light chains of SEQ ID NO:4 that lacks signal sequence MVLQTQVFISLLLWISGAYG (amino acid residues 1-20 of SEQ ID NO:4).
6. The modified immunoglobulin molecule of claim 1 , wherein the light chain further comprises a light chain CDR1 comprising RASESVDNYGISFMK (SEQ ID NO:20), a light chain CDR2 comprising AASNQGS (SEQ ID NO:21), and light chain CDR3 comprising QQSKEVPWTFGG (SEQ ID NO:22).
7. A modified immunoglobulin molecule, comprising:
a) a first antigen-binding site that specifically binds human VEGF, and
b) a second antigen-binding site that specifically binds human DLL4; and
wherein the first antigen-binding site comprises a heavy chain CDR1 comprising NYWMH (SEQ ID NO:17), a heavy chain CDR2 comprising DINPSNGRTSYKEKFKR (SEQ ID NO:18), and a heavy chain CDR3 comprising HYDDKYYPLMDY (SEQ ID NO:19); and
wherein the second antigen-binding site comprises a heavy chain CDR1 comprising TAYYIH (SEQ ID NO:13) or AYYIH (SEQ ID NO:79), a heavy chain CDR2 comprising YIX 1 X 2 YX 3 X 4 ATNYNQKFKG (SEQ ID NO:80), wherein X 1 is serine or alanine, X 2 is serine, asparagine, or glycine, X 3 is asparagine or lysine, and X 4 is glycine, arginine, or aspartic acid, and a heavy chain CDR3 comprising RDYDYDVGMDY (SEQ ID NO:16); and
wherein both the first and second-antigen binding sites comprise a light chain having at least 95% sequence identity to SEQ ID NO:4 that lacks signal sequence MVLQTQVFISLLLWISGAYG (amino acid residues 1-20 of SEQ ID NO:4).
8. The modified immunoglobulin molecule of claim 7 , wherein the heavy chain variable region of the second antigen-binding site comprises (i) a heavy chain CDR1 comprising TAYYIH (SEQ ID NO:13), (ii) a heavy chain CDR2 comprising YISNYNRATNYNQKFKG (SEQ ID NO:65), and (iii) a heavy chain CDR3 comprising RDYDYDVGMDY (SEQ ID NO:16).
9. The modified immunoglobulin molecule of claim 1 , wherein the heavy chain variable region of the second antigen-binding site comprises (i) a heavy chain CDR1 comprising TAYYIH (SEQ ID NO:13), (ii) a heavy chain CDR2 comprising YISNYNRATNYNQKFKG (SEQ ID NO:65), and (iii) a heavy chain CDR3 comprising RDYDYDVGMDY (SEQ ID NO:16).
10. The modified immunoglobulin molecule of claim 7 , which is a monoclonal antibody, a bispecific antibody, a monovalent bispecific antibody, a dual variable domain antibody, a chimeric antibody, a humanized antibody, a human antibody, or an antibody conjugate.
11. The modified immunoglobulin molecule of claim 7 , which is an IgG1 antibody, an IgG2 antibody, or an IgG4 antibody.
12. A pharmaceutical composition comprising the modified immunoglobulin molecule of claim 7 and a pharmaceutically acceptable carrier.
13. The modified immunoglobulin molecule of claim 7 , wherein both the first and second antigen-binding sites comprise a light chain having at least 97% sequence identity to SEQ ID NO:4 that lacks signal sequence MVLQTQVFISLLLWISGAYG (amino acid residues 1-20 of SEQ ID NO:4).
14. The modified immunoglobulin molecule of claim 13 , wherein both the first and second antigen-binding sites comprise a light chain having at least 99% sequence identity to SEQ ID NO:4 that lacks signal sequence MVLQTQVFISLLLWISGAYG (amino acid residues 1-20 of SEQ ID NO:4).
15. The modified immunoglobulin molecule of claim 14 , wherein both the first and second antigen-binding sites comprise a light chain comprising SEQ ID NO:4 that lacks signal sequence MVLQTQVFISLLLWISGAYG (amino acid residues 1-20 of SEQ ID NO:4).
16. The modified immunoglobulin molecule of claim 7 , wherein the light chain further comprises a light chain CDR1 comprising RASESVDNYGISFMK (SEQ ID NO:20), a light chain CDR2 comprising AASNQGS (SEQ ID NO:21), and light chain CDR3 comprising QQSKEVPWTFGG (SEQ ID NO:22).
17. A method of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the modified immunoglobulin molecule of claim 7 .
18. The method of claim 17 , wherein the cancer is selected from the group consisting of colorectal cancer, colon cancer, ovarian cancer, pancreatic cancer, lung cancer, liver cancer, breast cancer, kidney cancer, prostate cancer, gastrointestinal cancer, melanoma, cervical cancer, bladder cancer, glioblastoma, head and neck cancer, lymphoma, and leukemia.